Adaptimmune (NASDAQ: ADAP): Reiterating Buy Rating With Increased Price Target=$14

ADAP

Adaptimmune (ADAP), our open position, has several up-coming catalysts. We consider the shares as an excellent Buy here with increased first price target=$14.

Adaptimmune is developing affinity tuned SPEAR T cells (TCR technology) aimed at solid tumors. The company is a leader in TCR technology wh...

Adaptimmune (ADAP), our open position, has several up-coming catalysts. We consider the shares as an excellent Buy here with increased first price target=$14.

Adaptimmune is developing affinity tuned SPEAR T cells (TCR technology) aimed at solid tumors. The company is a leader in TCR technology wh...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics